## Shunya Arai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7394049/publications.pdf

Version: 2024-02-01

38	1,044 citations	567281 15	32
papers	citations	h-index	g-index
39 all docs	39 docs citations	39 times ranked	2239 citing authors

#	Article	IF	CITATIONS
1	Physical interaction between BAALC and DBN1 induces chemoresistance in leukemia. Experimental Hematology, 2021, 94, 31-36.	0.4	3
2	Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia. Experimental Hematology, 2021, 101-102, 42-48.e11.	0.4	6
3	CAMK2G is identified as a novel therapeutic target for myelofibrosis. Blood Advances, 2021, , .	5.2	2
4	Efficient production of human neutrophils from iPSCs that prevent murine lethal infection with immune cellÂrecruitment. Blood, 2021, 138, 2555-2569.	1.4	10
5	Posterior reversible encephalopathy syndrome concurrent with human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation. Journal of Infection and Chemotherapy, 2020, 26, 265-268.	1.7	3
6	Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. Leukemia and Lymphoma, 2020, 61, 1688-1694.	1.3	2
7	Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification. Leukemia, 2019, 33, 191-204.	7.2	41
8	Retrospective analysis on transient recurrence of steroid-sensitive acute graft-versus-host disease. Bone Marrow Transplantation, 2019, 54, 316-319.	2.4	1
9	A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination. Leukemia, 2019, 33, 1773-1782.	7.2	11
10	Cyclosporine Therapy in Patients with Transfusion-independent Non-severe Aplastic Anemia: A Retrospective Analysis. Internal Medicine, 2019, 58, 355-360.	0.7	7
11	Genetically Engineered Hematopoietic Progenitors Derived from Human Induced Pluripotent Stem Cells Achieve the Feeder-Free and Robust Production of Neutrophils with the Functional Capacity In Vivo. Blood, 2019, 134, 720-720.	1.4	0
12	ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells. Stem Cell Reports, 2018, 10, 1115-1130.	4.8	29
13	Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. Scientific Reports, 2018, 8, 15855.	3.3	24
14	Usefulness of presepsin for early detection of infections in patients with hematologic disorders. Clinica Chimica Acta, 2018, 486, 374-380.	1.1	3
15	Prognostic factors of Erdheim–Chester disease: a nationwide survey in Japan. Haematologica, 2018, 103, 1815-1824.	3.5	22
16	The Development of Acute Systemic Multiple Thrombosis after Achieving Remission during Systemic Glucocorticoid Therapy for Acquired Hemophilia A. Internal Medicine, 2018, 57, 2237-2241.	0.7	2
17	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. Leukemia Research, 2018, 74, 137-143.	0.8	7
18	Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. International Journal of Hematology, 2017, 106, 375-384.	1.6	17

#	Article	IF	CITATIONS
19	Adiponectin Enhances Quiescence Exit of Murine Hematopoietic Stem Cells and Hematopoietic Recovery Through mTORC1 Potentiation. Stem Cells, 2017, 35, 1835-1848.	3.2	34
20	A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). American Journal of Hematology, 2017, 92, 1324-1332.	4.1	9
21	A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia. Journal of Infection and Chemotherapy, 2017, 23, 788-790.	1.7	9
22	Clinical features of hematological disorders with increased large granular lymphocytes (LGLs): a retrospective study. Annals of Hematology, 2017, 96, 2113-2115.	1.8	2
23	Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. International Journal of Hematology, 2017, 105, 59-69.	1.6	13
24	Adiponectin Enhances Antibacterial Activity of Hematopoietic Cells by Suppressing Bone Marrow Inflammation. Immunity, 2016, 44, 1422-1433.	14.3	37
25	Modeling of hematologic malignancies by iPS technology. Experimental Hematology, 2015, 43, 654-660.	0.4	11
26	Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Experimental Hematology, 2015, 43, 849-857.	0.4	40
27	Recurrent CDC25C mutations drive malignant transformation in FPD/AML. Nature Communications, 2014, 5, 4770.	12.8	74
28	Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples. Experimental Hematology, 2014, 42, 816-825.	0.4	22
29	Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia. Blood, 2014, 124, 3587-3596.	1.4	16
30	JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. Blood, 2014, 124, 2996-3006.	1.4	36
31	Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. Journal of Clinical Investigation, 2014, 124, 528-542.	8.2	184
32	Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood, 2012, 119, 6234-6242.	1.4	143
33	NF-κB/TNF-α Positive Feedback Loop with Active Proteasome Machinery Supports Myeloid Leukemia Initiating Cell Capacity. Blood, 2012, 120, 654-654.	1.4	0
34	Evil represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood, 2011, 117, 3617-3628.	1.4	129
35	Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood, 2011, 117, 6304-6314.	1.4	79
36	Evil Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System. Blood, 2010, 116, 838-838.	1.4	0

#	Article	IF	CITATIONS
37	Evi-1 Is a Direct Target of MLL Oncoproteins in Hematopoietic Stem Cells. Blood, 2008, 112, 3807-3807.	1.4	9
38	Splenic Peliosis in a Patient with Aplastic Anemia during Danazol Therapy. International Journal of Hematology, 2007, 86, 329-332.	1.6	7